Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s COVID Manufacturing Deal With US Government Goes Well Beyond J&J Vaccine

Executive Summary

‘Wartime’ contract with BARDA will fund up to $268.8m in production site upgrades so Merck can also produce other COVID-19 vaccines and therapeutics as needed.

You may also be interested in...



Special Counsel Finds US FDA’s Dismissal Of Inspection Concerns Unreasonable

Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.

Pandemic Perspectives: How COVID May Reshape US Emergency Use Authorizations

FDA policy experts Jesse Goodman, Mark McClellan, Peter Lurie, David Bowen, Patti Zettler, and Aaron Kesselheim suggest ideas and points to consider in using the COVID-19 experience to assess whether standards for EUAs should be adjusted.

Pharma Gets Warm Spotlight At White House Event Showcasing J&J-Merck Collaboration

Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel